Since CDC has chosen a gross dereliction of duty in not performing weekly PRR analysis as specified in the January 29, 2021 VAERS Standard Operating Procedure document, weekly will be provided here.
Using the CDC’s methodology for performing the PRR safety signal analysis, the Covid-19 vaccines will be compared to all other vaccines combined and then also compared separately to the influenza vaccine and the vaccine against herpes zoster, as suggested in your paper. The analysis will include adverse events of special interest (as defined by the CDC), in addition to other select adverse events that are also of high interest. The analysis will include stratification by age and severity. The deadline for the analysis will be 12/2020 for the submission of the Covid-19 vaccines and 1990 for the submission of all other vaccines. We will only use US data. Corrections were made for missing age and death data (more than 20% of records are missing age data, which is clearly available in the narrative description) for this analysis.
This week’s PRR analysis uses the VAERS data files released on 09/22/2023 (data through 09/15/2023).
High-level graphical summary:
Full data downloads available below
For Covid-19 and non-Covid-19 vaccines:
For Covid-19 vaccines and flu vaccines:
For covid-19 and distemper vaccines:
